Research Article

Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis

Yingqing Chen,1 Indira Pandiri,1 Yeonsoo Joe,1 Hyo Jeong Kim,1 Seul-Ki Kim,1 Jeongmin Park,1 Jinhoon Ryu,2 Gyeong Jae Cho,2 Jeong Woo Park,1 Stefan W. Ryter,3 and Hun Taeg Chung1

1Department of Biological Sciences, University of Ulsan, Ulsan 680-749, Republic of Korea
2Department of Anatomy, School of Medicine and Institute of Health Sciences, Gyeongsang National University, Jinju 660-701, Republic of Korea
3Joan and Sanford I. Weill Department of Medicine, New York-Presbyterian Hospital, and Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical Center, New York, NY 10065, USA

Correspondence should be addressed to Hun Taeg Chung; chung@ulsan.ac.kr

Received 27 August 2015; Revised 24 November 2015; Accepted 30 November 2015

Academic Editor: Borna Relja

Copyright © 2016 Yingqing Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The selective type-3 phosphodiesterase inhibitor cilostazol and the antihyperlipidemic agent probucol have antioxidative, anti-inflammatory, and antithrombogenic properties. Moreover, cilostazol and probucol can regulate mitochondrial biogenesis. However, the combinatorial effect of cilostazol and probucol on mitochondrial biogenesis remains unknown. Endoplasmic reticulum (ER) stress is a well-known causative factor of nonalcoholic fatty liver disease (NAFLD) which can impair mitochondrial function in hepatocytes. Here, we investigated the synergistic effects of cilostazol and probucol on mitochondrial biogenesis and ER stress-induced hepatic steatosis. A synergistic effect of cilostazol and probucol on HO-1 and mitochondrial biogenesis-related genes expression was found in human hepatocellular carcinoma cells (HepG2) and murine primary hepatocytes. Furthermore, in an animal model of ER stress involving tunicamycin, combinatorial treatment with cilostazol and probucol significantly increased the expression of HO-1 and mitochondrial biogenesis-related genes and proteins, whereas it downregulated serum ALT, eIF2 phosphorylation, and CHOP expression, as well as the lipogenesis-related genes SREBP-1c and FAS. Based on these results, we conclude that cilostazol and probucol exhibit a synergistic effect on the activation of mitochondrial biogenesis via upregulation of HO-1, which confers protection against ER stress-induced hepatic steatosis.

1. Introduction

Mitochondria are ubiquitous membrane-bound organelles essential for cellular energy generation, which contribute many important metabolic functions including pyruvate and fatty acid oxidation, nitrogen metabolism, and heme biosynthesis. The mitochondria are the site of the electron transport chain which provides the bulk of cellular energy in the form of ATP [1, 2]. Mitochondrial biogenesis refers to the process by which new mitochondria are formed in the cell. The peroxisome proliferator-activated receptor-gamma (PPARγ) family of transcriptional coactivators includes PPARγ coactivator (PGC)-1 alpha (PGC-1α), PGC-1β, and the PGC-related coactivator, PRC. Of these, PGC-1α has been identified as a master regulator of mitochondrial biogenesis. PGC-1α can coactivate the nuclear respiratory factor-1 (NRF-1) and subsequently the mitochondrial transcription factor A (TFAM), which is directly responsible for transcribing nuclear-encoded mitochondrial proteins [3–5]. Hepatocytes are rich in mitochondria, which play
an important role in hepatocyte metabolism. Fatty acid oxidation mainly occurs in the liver for energy production. Impaired mitochondrial β-oxidation may cause NAFLD [6]. Expression of mtDNA-encoded polypeptides [7] and activity of complexes I, III, IV, and V [8] were reduced in patients with NASH.

Heme oxygenase-1 (HO-1) is a major stress-inducible protein in mammalian cells. In previous studies, HO-1 has been shown to regulate mitochondrial biogenesis in cardiomyocytes via NF-E2-related factor-2 (NRF-2) mediated transcriptional control of nuclear respiratory factor-1 (NRF-1) [9]. The promoter region of the HO-1 gene contains multiple copies of antioxidant response elements that are critical for stress-inducible gene expression and that are tightly regulated by the transcription factor Nrf2 [10]. Recently, we demonstrated that cilostazol increases the expression of genes involved in mitochondrial biogenesis, including NRF-1, PGCG-1α, and TFAM via upregulating the production and activity of HO-1 in a human hepatoma cell line (HepG2) [11]. Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) has been demonstrated as a selective inhibitor of type-3 phosphodiesterase (PDE3), which can increase the intracellular level of 3′,5′-cyclic adenosine monophosphate (cAMP) [12]. As an antithrombotic drug, cilostazol is widely used for the treatment of thrombotic vascular disease due to its antiplatelet aggregation properties [13]. Moreover, cilostazol inhibits LPS-induced apoptosis via reducing the production of intracellular reactive oxygen species (ROS) [14] and protects mice against endotoxin shock via MAPK inhibition and NF-κB inactivation [15]. Cilostazol can also protect mice against carbon tetrachloride-induced liver fibrosis by attenuating hepatic stellate cell activation [16]. In addition, cilostazol has been shown to promote mitochondrial biogenesis in human umbilical vein endothelial cells (HUVECs) through activating the expression of PGC-1α [17].

Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) has been demonstrated as a selective inhibitor of type-3 phosphodiesterase (PDE3), which can increase the intracellular level of 3′,5′-cyclic adenosine monophosphate (cAMP) [12]. As an antithrombotic drug, cilostazol is widely used for the treatment of thrombotic vascular disease due to its antiplatelet aggregation properties [13]. Moreover, cilostazol inhibits LPS-induced apoptosis via reducing the production of intracellular reactive oxygen species (ROS) [14] and protects mice against endotoxin shock via MAPK inhibition and NF-κB inactivation [15]. Cilostazol can also protect mice against carbon tetrachloride-induced liver fibrosis by attenuating hepatic stellate cell activation [16]. In addition, cilostazol has been shown to promote mitochondrial biogenesis in human umbilical vein endothelial cells (HUVECs) through activating the expression of PGC-1α [17].

Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) has been demonstrated as a selective inhibitor of type-3 phosphodiesterase (PDE3), which can increase the intracellular level of 3′,5′-cyclic adenosine monophosphate (cAMP) [12]. As an antithrombotic drug, cilostazol is widely used for the treatment of thrombotic vascular disease due to its antiplatelet aggregation properties [13]. Moreover, cilostazol inhibits LPS-induced apoptosis via reducing the production of intracellular reactive oxygen species (ROS) [14] and protects mice against endotoxin shock via MAPK inhibition and NF-κB inactivation [15]. Cilostazol can also protect mice against carbon tetrachloride-induced liver fibrosis by attenuating hepatic stellate cell activation [16]. In addition, cilostazol has been shown to promote mitochondrial biogenesis in human umbilical vein endothelial cells (HUVECs) through activating the expression of PGC-1α [17].

Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) has been demonstrated as a selective inhibitor of type-3 phosphodiesterase (PDE3), which can increase the intracellular level of 3′,5′-cyclic adenosine monophosphate (cAMP) [12]. As an antithrombotic drug, cilostazol is widely used for the treatment of thrombotic vascular disease due to its antiplatelet aggregation properties [13]. Moreover, cilostazol inhibits LPS-induced apoptosis via reducing the production of intracellular reactive oxygen species (ROS) [14] and protects mice against endotoxin shock via MAPK inhibition and NF-κB inactivation [15]. Cilostazol can also protect mice against carbon tetrachloride-induced liver fibrosis by attenuating hepatic stellate cell activation [16]. In addition, cilostazol has been shown to promote mitochondrial biogenesis in human umbilical vein endothelial cells (HUVECs) through activating the expression of PGC-1α [17].

Based on the pharmacological profiles of cilostazol and probucol, the combination of these two drugs has shown synergistic effects on reducing ischemic infarct in the rat brain compared to cilostazol or probucol monotherapy [23]. In low density lipoprotein receptor-deficient mice fed with a high fat diet, the combinatorial effects of cilostazol and probucol significantly decreased atherosclerotic lesions relative to that of cilostazol and probucol alone [24]. The combinatorial effects of cilostazol and probucol also attenuated hypercholesterolemia-induced exacerbation in ischemic brain injury via decreasing MCP-1 expression and CD11b and GFAP immune reactivity in the ischemic cortex from apolipoprotein E (ApoE) knockout mice [25].

Because cilostazol and probucol both increase HO-1 expression and have antioxidant properties, we hypothesized that the combination of low doses of these two drugs may exert synergistic effects on mitochondrial biogenesis via increasing the production and activity of HO-1 in a HepG2 human hepatoma cell line. Our results demonstrate that the combination of cilostazol and probucol significantly increased the expression of HO-1, PGC-1α, NRF-1, and TFAM relative to cilostazol and probucol individually. Furthermore, we also demonstrated synergistic effects of cilostazol and probucol on increasing ATP production and mitochondrial DNA (mtDNA) content.

2. Materials and Methods

2.1. Reagents. Cilostazol (OPC-13013), [6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone], and probucol, [4,4′-(isopropylidenedithio)bis(2,6-di-tert-butylphenol)], were donated by Otsuka Pharmaceutical Co. Ltd. (Tokushima, Japan). Tunicamycin (TM) was purchased from Sigma-Aldrich (St Louis, MO, USA).

2.2. Cell Culture. HepG2 cells were obtained from the Korean cell line bank (Seoul, Korea). HepG2 cells were cultured in DMEM (Gibco, Grand Island, NY) containing 10% FBS and 1% penicillin-streptomycin solution at 37°C in humidified incubators containing 5% CO₂. C57BL/6 cells were treated with cilostazol at various concentrations (0, 0.1, 0.3, 1, and 3 μM) with or without probucol (0.1 μM) for 4 h.

2.3. Animals. Animals were maintained in a specific pathogen-free facility. Animal studies were approved by the university of Ulson Animal Care and Use Committee. The mice were maintained under specific pathogen-free conditions at 18–24°C and 40–70% humidity, with a 12-hour light-dark cycle. Food and drinking water were available ad libitum. Male C57BL/6 wild-type mice (6 weeks old) were purchased from ORIENT (Pusan, Korea). C57BL/6 mice were assigned randomly into five groups (CON, TM, TM + PB, TM + CZ, and TM + PB + CZ), with six mice in each group. C57BL/6 mice were injected with cilostazol (3 mg/kg body weight) and probucol (1 mg/kg body weight) individually or combinatorially once daily for 3 days and then they were sacrificed after challenging with tunicamycin (3 mg/kg body weight) for 24 h. BALB/c HO-1 knockout mice were provided by Dr. Mark A. Perrella (Brigham and Women’s Hospital, Boston, MA).

2.4. Isolation of Primary Hepatocytes. Primary hepatocytes from wild-type (WT) and HO-1 knockout (KO) mice were isolated. Livers were perfused with Ca²⁺- and Mg²⁺-free HBSS containing EGTA (2.5 mM) and then digested with a
coli]-blocking with 5% skim milk in PBS, membranes were incubated with polyvinylidenedifluoride membranes (GE healthcare). After 2.5. Western Blot Analyses. Harvested liver tissues and cells were lysed with mammalian lysis buffer containing phosphatase and protease inhibitors. Equal amounts of cell lysates were measured with the BCA protein assay reagent (Pierce Biotechnology, Rockford, IL). Lysates were boiled in sample buffer containing β-mercaptoethanol for 5 min. Proteins were then subjected to SDS-PAGE and transferred to membranes. After 2 min at 700 rpm and resuspended with HBSS. After the pellet suspensions were centrifuged with 25% Percoll for 5 min at 800rpm with the brake option off, the pellets were washed with DMEM supplemented with 10% FBS, and then cells were seeded into collagen precoated 100 mm tissue culture plates. After 24 h, nonadherent cells were removed by aspiration, and fresh medium was added.

2.6. Reverse Transcriptase PCR. Total RNA from cells was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. In brief, total RNA (2 μg) was used to synthesize the first strand cDNA by using oligo-dT primers and M-MLV reverse transcriptase (Promega, Madison, WI). The synthesized cDNA was subjected to the PCR-based amplification. The following primers were used: hHO-1 forward, 5'-CTCGGTGCTAGTGTCTAGAGTTTTA-3', reverse, 5'-GGATTTGGGGCTGCTGGTTTC-3'; mNRF-1 forward, 5'-TTGAGGGCAACGCAAGAAG-3', reverse, 5'-TTGGTGCCCTGAGTTTGTGTT-3'; miTAM forward, 5'-CAGCCAAGTGTGACCCATCA-3', reverse, 5'-AATAGAAACCCGCTCAG-3'; gGAPDH forward, 5'-AGGCCGGTGCTGCTAGTGTGTTT-3', reverse, 5'-TGGCTGCTTCACCCCTTCT-3'. The expression of GAPDH was measured as an internal control. The relative band density was analyzed by using ImageJ software (US National Institutes of Health, Bethesda, MD).

2.7. Real-Time Quantitative RT-PCR. Total RNA was prepared using TRIzol reagent (Invitrogen). 2 μg of total RNA was used to synthesize the first strand cDNA by using oligo-dT primers and MMLV reverse transcriptase (Promega, Madison, WI) according to the manufacturer's instructions. Real-time quantitative PCR was performed with SYBR Green qPCR Master Mix (2x, USB Production; Affymetrix) on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA). The following primer pairs were used: hHO-1 forward, 5'-CAGGAAGTCTGCTGACCATTACG-3', reverse, 5'-AGCAAACGTTCGCCCA CGGAA-3', hPGC-1α forward, 5'-GAGAGGGCCCAAAGAAG-3', reverse, 5'-AAATACACCGGCCGCTTCT-3', hNRF-1 forward, 5'-CCATCTGTTGGCCTGAAG-3', reverse, 5'-TGGCTGCCGTTCAATGAA-3', hTFAM forward, 5'-GAACACTACCCATATTTAAGCT CA-3', reverse, 5'-GAATCAAGAAGTG TCCCTCCA-3', hGAPDH forward, 5'-CAATGATCTCCCTCCTC-3', reverse, 5'-AGCATCGCCCACTTGCAGT-3'; COX III forward, 5'-CTGCTGGAAAAACACTTCGGAATA-3', reverse, 5'-GCTGTACGTGTTGATGTTGCTG-3', mTFAM forward, 5'-GGGAATGTGGAGCGTGCTAAAA-3', reverse, 5'-GCTGTACGTGTTGATGTTGCTG-3', mNRF-1 forward, 5'-GGAATGTGGAGCGTGCTAAAA-3', reverse, 5'-GCTGTACGTGTTGATGTTGCTG-3'; mSREBP1 forward, 5'-TGCTGGAAAAACACTTCGGAATA-3', reverse, 5'-GAATCAAGAAGTG TCCCTCCA-3', mTFAM forward, 5'-GGGAATGTGGAGCGTGCTAAAA-3', reverse, 5'-GCTGTACGTGTTGATGTTGCTG-3'.

2.8. Transfection of siRNAs. Small interfering RNAs (siRNAs) against human HO-1 (siHO-1) (SI02780533) were purchased from QIAGEN (Hilden, Germany) and negative control siRNA (scRNA) (AM4611) was purchased from Ambion (Austin, TX). HepG2 cells (7 × 10⁶) were transfected with siHO-1 and scRNA by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 24 h.

2.9. Hepatocellular Damage Assay. Hepatic injury was assessed by serum alanine transaminase (ALT) levels with use of the EnzyChrom Alanine Transaminase Assay Kit (Bio-Assay Systems, Hayward, CA).

2.10. ATP Measurements. Cellular ATP content was determined by means of the CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

2.11. mtDNA Analysis. Total DNA was extracted from primary hepatocytes by use of AccuPrep Genomic DNA Extraction Kit (Bioneer, Daejeon, Korea). mtDNA copy number was measured by real-time quantitative PCR. The following primers for mtDNA were used: mouse cytochrome b (Mus musculus domesticus mitochondrion) forward primer, 5'-CCACTTTCACTTACCATTTA-3', reverse primer, 5'-ATCTGAGCTGATTTAATC-3'. For nuclear DNA (nDNA) the following were used: mouse 18S rRNA forward primer, 5'-GGGAGCCCTGAGGAACGGC-3', reverse primer, 5'-GGTGCGGAGTGGAATTT-3'. Relative amounts of mtDNA and nDNA copy numbers were compared.

2.12. Measurements of Triglyceride. Hepatic triglyceride was assessed by triglyceride colorimetric assay kit (Cayman Chemical, Ann Arbor, Michigan, USA). Briefly, liver tissues (50 mg), HepG2 cells (1 × 10⁶), and primary hepatocytes (1 × 10⁶) were homogenized in 200 μL diluted Standard Diluents. After 10,000 × g centrifugation for 10 minutes, supernatant were transferred to another tube. Before assaying, tissue samples required dilution at least 1:5, while there was no need for the dilution of serum or cell samples. Then we need 10 μL serum and cell supernatant for the assay.

2.13. Measurements of Hepatic Triglyceride. Hepatic triglyceride was assessed using the triglyceride colorimetric assay kit (Cayman Chemical, Ann Arbor, Michigan, USA). Briefly, 50 mg liver tissues were homogenized in 200 μL diluted Standard Diluents. After 10,000 × g centrifugation for 10 minutes, supernatants were transferred to another tube. Before assaying, tissue samples required dilutions of at least 1:5 (v/v) by Standard Diluent.

2.14. Liver Histology. To detect the pathological changes, liver tissues were fixed in 10% neutral-buffered formalin solution and then dehydrated in graded alcohol, embedded in paraffin, sectioned into 4 μm thick sections, and stained with hematoxylin and eosin (H&E).

2.15. Statistical Analysis. All values are expressed as means ± SE. Statistical differences between groups were evaluated by one-way ANOVA with post hoc Tukey’s honestly significant difference (HSD) test. Data were analyzed and presented with GraphPad Prism software version 5 (GraphPad Software, San Diego, CA).

3. Results

3.1. Synergistic Effect of Cilostazol and Probucol on HO-1 Expression in HepG2 Cells and Primary Hepatocytes. Due to previous studies reporting that both cilostazol and probucol can enhance HO-1 expression, we first evaluated the effect of the combined treatment of cilostazol and probucol on HO-1 mRNA expression by RT-PCR and real-time PCR. We treated HepG2 cells with cilostazol at various concentrations (0, 0.1, 0.3, 1, and 3 μM) with or without probucol (0.1 μM) for 4 h. As shown in Figures 1(a) and 1(b), cilostazol enhanced the mRNA expression of HO-1 in a dose-dependent manner, whereas the combined treatment with cilostazol and probucol increased HO-1 mRNA expression much higher than the corresponding dose of cilostazol alone. To confirm the synergistic effect of cilostazol and probucol on HO-1 expression, we treated primary hepatocytes from C57BL/6 mice with probucol (0.1 μM) and cilostazol (3 μM) individually or in combination for 4 h. Then we assessed the expression of HO-1 mRNA (Figure 1(c)) and protein levels (Figure 1(d)). Consistent with results from HepG2 cells, the combination treatment induced a significant increase in HO-1 expression compared to the individual treatments alone. These results suggest that cilostazol and probucol can exert a synergistic effect on the upregulation of HO-1 mRNA expression in HepG2 cells and in primary hepatocytes.

3.2. Combination of Cilostazol and Probucol Exerts Beneficial Effects on Mitochondrial Biogenesis. HO-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of Nrf-1 [9]. We have shown that cilostazol attenuates hepatic ischemia/reperfusion injury via HO-1 dependent activation of mitochondrial biogenesis [11]. According to previous studies, we next assessed the expression of mitochondrial biogenesis-related genes PGC-1α, TFAM, and NRF-1 in response to the combined treatment of cilostazol and probucol. HepG2 cells were treated with cilostazol at various concentrations (0, 0.1, 0.3, 1, and 3 μM) in the absence or presence of probucol (0.1 μM) for 4 h. RT-PCR (Figure 2(a)) and real-time RT-PCR (Figures 2(b), 2(c), and 2(d)) were performed to detect mRNA expression of mitochondrial biogenesis-related genes. As expected, the combined treatment of cilostazol and probucol significantly enhanced PGC-1α, TFAM, and NRF-1 mRNA expression compared to the corresponding dose of cilostazol alone. To confirm the beneficial effects of combinatorial treatment on mitochondrial biogenesis, we next treated primary hepatocytes with probucol (0.1 μM) and cilostazol (3 μM) individually as well as with their combination to test the effect on mitochondrial biogenesis-related genes at the mRNA and protein level. Consistent with results observed from HepG2 cells, combinatorial treatment of cilostazol and probucol showed a significant increase on PGC-1α, TFAM, and NRF-1 mRNA level (Figure 2(e)) as well as on PGC-1α, COX III, and COX IV protein level (Figure 2(f)) compared to their individual treatment. To evaluate whether the increase of mitochondrial biogenesis was mediated by HO-1, we pretreated primary hepatocytes with ZnPP, an inhibitor of HO activity, for 30 min. Additionally, we treated primary hepatocytes from HO-1 WT and KO mice with probucol (0.1 μM) and cilostazol (3 μM) for 4 h to assess the mRNA expression of PGC-1α, TFAM, and NRF-1. As shown in Figures 2(g) and 2(h), cilostazol and probucol had a synergistic effect on mitochondrial biogenesis-related genes, whereas they failed to increase these genes in the presence of ZnPP or in the absence of HO-1. These results indicated that cilostazol and probucol have a beneficial effect on mitochondrial biogenesis mediated by HO-1 expression.
3.3. Combinatorial Treatment of Cilostazol and Probucol Ameliorates Tunicamycin-Induced Mitochondrial Dysfunction. Endoplasmic reticulum (ER) and mitochondria exist in physical proximity, which supports communication between these two organelles, including synthesis and transfer of lipids, exchange of calcium ions, mitochondrial ATP production, and apoptosis. Stressors on the ER can induce mitochondrial damage [26]. Therefore, we hypothesized that the combinatorial treatment of cilostazol and probucol may ameliorate ER stress-induced mitochondrial dysfunction via the induction of mitochondrial biogenesis. To validate the protective effect of cilostazol and probucol on mitochondrial function, we pretreated primary hepatocytes with probucol (0.1 μM) and cilostazol (3 μM) alone as well as with their combination for 30 min followed by stimulation with tunicamycin (10 μg/mL), an ER stress inducer, for another 18 h. The quantity change of mitochondria and mtDNA content was detected in primary hepatocytes by MitoTracker staining.
Figure 2: Continued.
Our results showed that ER stress induced by tunicamycin (Figure 3(a)) and real-time PCR (Figure 3(b)), respectively. Our results showed that ER stress induced by tunicamycin treatment of cilostazol (CZ) and probucol (PB) on mitochondrial biogenesis-related gene expression. HepG2 cells were treated with cilostazol at various concentrations (0, 0.1, 0.3, 1, and 3 μM) with or without probucol (0.1 μM) for 4 h and PGC-1α, TFAM, and NRF-1 mRNA expression were detected by RT-PCR (a) and real-time RT-PCR (b, c, and d). Primary hepatocytes isolated from C57BL/6 mice were treated with probucol (0.1 μM) and cilostazol (3 μM) individually as well as with their combination for 4 h. Mitochondrial biogenesis-related genes PGC-1α, TFAM, and NRF-1 were measured by RT-PCR (e), and mitochondrial-related proteins PGC-1α, COX III, and COX IV were measured by Western blotting (f). Primary hepatocytes from HO-1 WT mice were pretreated in the absence or presence of ZnPP (10 μM) and then were treated with probucol (0.1 μM) and cilostazol (3 μM) individually or in combination for 4 h and then the expression of mitochondrial biogenesis-related genes PGC-1α, TFAM, and NRF-1 was detected by RT-PCR (g). Furthermore, primary hepatocytes from HO-1 KO mice were also analyzed by RT-PCR to detect mitochondrial biogenesis-related genes expression (h). Bar graphs, right panels of (a), (e), and (f), as well as lower panels of (g) and (h) are summary data of normalized densitometric ratios. Quantitative data are expressed as means ± SE; n = 3. *P < 0.05, **P < 0.01, and ***P < 0.001 versus cells without treatment; ### versus cells treated with probucol; $$$ versus cells treated with cilostazol.

(Figure 3(a)) and real-time PCR (Figure 3(b)), respectively. Our results showed that ER stress induced by tunicamycin reduced MitoTracker-positive staining and mtDNA content. However, the combinatorial treatment of cilostazol (3 μM) and probucol (0.1 μM) significantly increased mtDNA quantity and MitoTracker-positive staining compared with their individual treatments in tunicamycin-challenged cells. In addition, the combinatorial treatment of cilostazol and probucol also significantly increased ATP production during stimulation with tunicamycin, whereas it failed to enhance ATP production in the absence of HO-1 (Figure 3(c)). We further examined the expression of HO-1 and mitochondrial biogenesis-related genes PGC-1α, TFAM, and NRF-1 as well as related proteins PGC-1α, COX III, and COX IV by RT-PCR (Figure 3(d)) and Western blot (Figure 3(e)), respectively. Combinatorial treatment of cilostazol and probucol in primary hepatocytes significantly increased these genes and proteins during tunicamycin challenge compared with their individual treatments alone. In contrast, these gene expression changes were not evident in HO-1 deficient cells (Figure 3(f)) or in HepG2 cells transfected with HO-1 siRNA (Figure 3(g)). These results suggest that cilostazol and probucol have a synergistic protective effect on ER stress-induced mitochondrial dysfunction via promotion of mitochondrial DNA biogenesis, ATP production, and related gene expression, which was mediated by HO-1 expression.

3.4. Combinatorial Treatment of Cilostazol and Probucol Ameliorates Tunicamycin-Induced Hepatosteatosis in Mouse Model. Increasing evidence suggests that hepatic ER stress increases nonalcoholic fatty liver disease (NAFLD) in several animal models. Moreover, ER stress leads to lipid accumulation through upregulation of lipogenesis-related genes SREBP-1c and FAS in normal hepatic and hepatoma cells [27, 28]. To confirm the combinatorial effect of cilostazol and probucol on ER stress-induced hepatic steatosis, we injected C57BL/6 mice with cilostazol (3 mg/kg body weight) and probucol (1 mg/kg body weight) individually or combinatorially once daily for 3 days then sacrificed mice after challenging them with tunicamycin (3 mg/kg body weight) for 24 h. In agreement with the histological analysis, lipid accumulation and liver injury were evident in tunicamycin-treated mice. However, the combinatorial treatment of cilostazol and probucol markedly decreased lipid accumulation and improved the ballooning degeneration of hepatocytes in response to tunicamycin stimulation when compared to
Figure 3: Continued.
their individual treatments (Figure 4(a)). Furthermore, we tested SREBP-1c (Figure 4(b)) and FAS (Figure 4(c)) mRNA expression in liver tissues as well as serum triglyceride concentration (Figure 4(d)), liver tissues (Figure 4(e)), HepG2 cells (Figure 4(f)), and primary hepatocytes (Figure 4(g)). The increased mRNA level of SREBP-1c and FAS and serum triglyceride concentration were significantly decreased by combinatory treatment of cilostazol and probucol compared with their individual treatments. To evaluate the liver damage induced by tunicamycin, we next detected serum ALT concentration (Figure 4(b)) and protein level of the ER stress markers p-eIF2α and CHOP (Figure 4(i)) in liver tissues. Consistent with the observed results, combination of cilostazol and probucol drastically decreased the serum ALT concentration, as well as p-eIF2α and CHOP expression under the condition of tunicamycin. Moreover, the expression of HO-1 and mitochondrial biogenesis-related genes was detected by real-time RT-PCR (Figure 4(j)) and Western blot analysis (Figure 4(k)). Combinatorial treatment of cilostazol and probucol significantly increased HO-1 and mitochondrial biogenesis-related genes under the tunicamycin stimulation in liver tissues compared to their individual treatments. Taken together, these results suggested that cilostazol and probucol exhibited synergistic effect on protection of hepatic steatosis caused by the ER stress inducer tunicamycin.

4. Discussion

Mitochondrial biogenesis is defined as the growth and division of preexisting mitochondria, which can be induced in adult muscle in response to exercise or chronic electrical stimulation. This kind of physiological control is considered as an adaptation to facilitate increased oxygen utilization [29, 30]. Reduction in mitochondrial function has been found to be associated with the pathology of several human diseases, such as type 2 diabetes and Alzheimer’s disease [31].
Figure 4: Continued.
Also, our laboratory found that mitochondrial dysfunction was associated with hepatic ischemia/reperfusion injury [11]. Mitochondria play an important role in hepatocyte metabolism, being the primary site for the oxidation of fatty acids and oxidative phosphorylation. Accumulation of FFAs in the liver is implicated in the pathogenesis of NAFLD [6]. Although the mechanisms for the pathogenesis of NAFLD are still unknown, they may be related to mitochondrial dysfunction including depletion of mitochondrial DNA (mtDNA), decreased activity of respiratory chain complexes, and impaired mitochondrial β-oxidation [32–34]. Moreover, NAFLD is caused by ER stress-induced mitochondrial dysfunction [35, 36]. To preserve the functional integrity of mitochondria, HO-1 plays an important role in recovering impaired mitochondria by ER stress [27].

Heme oxygenase (HO) is the rate-limiting enzyme in the degradation of heme, which generates biliverdin, carbon monoxide (CO), and iron. Two distinct isoforms of HO have been identified and cloned including HO-1 and HO-2 [28]. Previous studies have shown the critical importance of HO-1 expression in mediating antioxidant, anti-inflammatory, and antiapoptotic effects [37–39]. Recent studies have demonstrated the coupling of mitochondrial biogenesis to anti-inflammation through HO-1 activity in a murine sepsis model [40]. HO-1 has been also suggested to regulate mitochondrial biogenesis via NF-E2-related factor-2 (Nrf2-) mediated transcriptional control of nuclear respiratory factor-1 (NRF-1) as well as the PGC-1α coactivator and mitochondrial transcription factor A (TFAM) in cardiomyocytes [9, 41]. For this reason, we have studied the synergistic effect of cilostazol and probucol on the HO-1 expression.

Cilostazol, as a selective inhibitor of PDE3 used to increase the intracellular level of cAMP [12], is widely used for the treatment of thrombotic vascular disease due to its antiplatelet aggregation functions [13]. In recent studies, cilostazol was shown to induce HO-1 expression to inhibit inflammation in J774 murine macrophages via the Nrf2 and PI3K/AKT signal pathways [42]. Probucol is a potent lipid-soluble antioxidant, which has been reported to possess strong antiatherogenic properties [18]. Also, probucol increases HO-1 expression and activity in balloon-injured rabbit aortas and rabbit aortic smooth muscle cells, which confers protection from atherosclerosis [22] and inhibits smooth muscle cell proliferation [21]. Although previous studies have demonstrated that either cilostazol or probucol upregulates HO-1 expression, little is known on the combinatorial effect of these two chemicals on HO-1 production as well as on mitochondrial DNA biogenesis. In this study, HepG2 cells were initially treated with a combination of cilostazol and probucol, and we found that the combinatorial effect on increasing HO-1 mRNA expression is much higher than the effect of cilostazol alone especially at the optimal combination doses (3 μM and 0.1 μM), respectively.

To investigate the synergistic effect of cilostazol and probucol in activating mitochondrial biogenesis via induction of HO-1, the expression of PGC-1α, TFAM, NRF-1, 

Figure 4: Combinatorial treatment of cilostazol (CZ) and probucol (PB) ameliorates tunicamycin- (TM-) induced hepatosteatosis in vivo. C57BL/6 mice were pretreated with cilostazol (3 mg/kg body weight) and probucol (1 mg/kg body weight) individually or combinatorially once daily for 3 days by intraperitoneal injection. The mice were sacrificed after challenge with tunicamycin (3 mg/kg body weight) for 24 h. Liver tissues were excised and representative liver histology is shown by H&E staining (a). Liver sections were, respectively, from CON (A), TM (B), TM + PB (C), TM + CZ (D), and TM + PB + CZ (E) treated mice. The expression of lipogenesis-related genes SREBP-1c and FAS in liver was measured by real-time RT-PCR (b and c). Triglyceride levels of serum (d), liver tissues (e), HepG2 cells (f) and primary hepatocytes (g), and ALT concentrations (h) were measured. For liver ER stress related proteins, p-eIF2α and CHOP were measured by Western blot (i). The expression of HO-1 and mitochondrial biogenesis-related genes PGC-1α, TFAM, and NRF-1, as well as related proteins PGC-1α, COX III, and COX IV, was measured by real-time RT-PCR (j) and Western blot (k), respectively. Bar graphs, left panels of (i) and (k), are summary data of normalized densitometric ratios. All mice were separated into experimental groups (n = 6 mice per group). Quantitative data are expressed as means ± SE; n = 3. *P < 0.05, **P < 0.01, and ***P < 0.001 versus cells without treatment; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus cells treated with tunicamycin; †P < 0.05, ††P < 0.01, and †††P < 0.001 versus cells treated with probucol and tunicamycin; ‡P < 0.05, ‡‡P < 0.01, and ‡‡‡P < 0.001 versus cells treated with cilostazol and tunicamycin.
complex III, and complex IV was measured in HepG2 cells or primary hepatocytes from wild-type or HO-1 knockout mice (Hmox1−/−) (Figure 2). Mitochondrial biogenesis, which is controlled by several key factors including PGC-1α, maintains mitochondrial populations and mitochondrial homeostasis. PGC-1α acts as a cardinal transcriptional regulator of mitochondrial biogenesis by activating nuclear respiratory factor-1 (NRF-1). TFAM activated by PGC-1α and NRF-1 regulates the transcription of nuclear genes encoding mitochondrial proteins [43, 44]. The mitochondrial abnormalities in liver also are related to the low levels of complexes I, III, IV, and V [8]. By measuring the levels of PGC-1α, TFAM, NRF-1, complex III, and complex IV in the deficiency of HO-1, we have found that HO-1 plays a critical role in the synergic effects of cilostazol and probucol on mitochondrial biogenesis.

ER stress promotes lipid drop formation in human adipose and liver tissue [6] and may promote NAFLD and metabolic syndrome [45]. Tunicamycin, as an ER stressor, decreases mitochondrial biogenesis (Figure 3) and increases lipogenesis in vivo (Figure 4). ER stress-induced ROS [46] may induce HO-1 expression as defense against oxidative stress in the early stage [47] and also increase PGC-1α and PGC-1β for regulation of ROS defense mechanisms [48]. Therefore, although HO-1 and PGC-1 expressions were induced by tunicamycin to some degree in our experiments, this was not sufficient to protect mitochondria against functional impairment by ER stress. Finally, combinatorial treatment of cilostazol and probucol improved mitochondrial dysfunction via enhanced HO-1 expression in the presence of ER stress.

Taken together, we demonstrate for the first time that cilostazol and probucol have a beneficial synergistic effect on HO-1 mRNA expression and on activation of mitochondrial biogenesis at relatively low doses. These findings provide new clues for the development of new therapeutics aimed at metabolic diseases.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Yingqing Chen and Indira Pandiri contributed equally to this work.

Acknowledgments

This work was supported by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A6A1030318) and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2012M3A9C3048687) and NRF-2014R1A1A2007525 and Otsuka Pharmaceutical Co., Ltd.

References

[1] R. S. Balaban, “Regulation of oxidative phosphorylation in the mammalian cell,” The American Journal of Physiology—Cell Physiology, vol. 258, no. 3, pp. C377–C389, 1990.
[2] Y. Hatefi, “The mitochondrial electron transport and oxidative phosphorylation system,” Annual Review of Biochemistry, vol. 54, pp. 1015–1069, 1985.
[3] Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1,” Cell, vol. 98, no. 1, pp. 115–124, 1999.
[4] U. Andersson and R. C. Scarpulla, “PGC-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor 1-dependent transcription in mammalian cells,” Molecular and Cellular Biology, vol. 21, no. 11, pp. 3738–3749, 2001.
[5] H. Escrivá, A. Rodriguez-Peña, and C. G. Vallejo, “Expression of mitochondrial genes and of the transcription factors involved in the biogenesis of mitochondria Tiam, NRF-1 and NRF-2, in rat liver, testis and brain,” Biochimie, vol. 81, no. 10, pp. 965–971, 1999.
[6] Y. Wéi, R. S. Rector, J. P. Thfyfault, and J. A. Ibdaah, “Nonalcoholic fatty liver disease and mitochondrial dysfunction,” World Journal of Gastroenterology, vol. 14, no. 2, pp. 193–199, 2008.
[7] E. Santamaría, M. A. Avila, M. U. Latasa et al., “Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 6, pp. 3065–3070, 2003.
[8] M. Pérez-Carreras, P. Del Hoyo, M. A. Martín et al., “Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis,” Hepatology, vol. 38, no. 4, pp. 999–1007, 2003.
[9] C. A. Piantadosi, M. S. Carraway, A. Babiker, and H. B. Sullman, “Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1,” Circulation Research, vol. 103, no. 11, pp. 1232–1240, 2008.
[10] J. Alam, D. Stewart, C. Touchard, S. Boinapally, A. M. K. Choi, and J. L. Cook, “Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene,” The Journal of Biological Chemistry, vol. 274, no. 37, pp. 26071–26078, 1999.
[11] Y. Joe, M. Zheng, H. J. Kim et al., “Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 309, no. 1, pp. G21–G29, 2015.
[12] Y. Kimura, T. Tani, T. Kanbe, and K. Watanabe, “Effect of cilostazol on platelet aggregation and experimental thrombosis,” Arzneimittel-Forschung, vol. 35, no. 7, pp. 1144–1149, 1985.
[13] C. Lugnier, “Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents,” Pharmacology and Therapeutics, vol. 109, no. 3, pp. 366–398, 2006.
[14] K. Y. Kim, H. K. Shin, J. M. Choi, and K. W. Hong, “Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells,” The Journal of Pharmacology and Experimental Therapeutics, vol. 300, no. 2, pp. 709–715, 2002.
[15] W. S. Park, W.-K. Jung, D.-Y. Lee et al., “Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition
Oxidative Medicine and Cellular Longevity

and NF-kappaB inactivation: not involved in cAMP mechanisms," International Immunopharmacology, vol. 10, no. 9, pp. 1077–1085, 2010.

[16] S. Saito, K. Hata, K. Iwasako et al., "Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis," Hepatology Research, vol. 44, no. 4, pp. 460–473, 2014.

[17] L. Zuo, Q. Li, B. Sun, Z. Xu, and Z. Ge, "Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1alpha," Biochemical and Biophysical Research Communications, vol. 433, no. 1, pp. 52–57, 2013.

[18] M. Kuzuya and F. Kuzuya, "Probucol as an antioxidant and antithromogenic drug," Free Radical Biology and Medicine, vol. 14, no. 1, pp. 67–77, 1993.

[19] G. A. A. Ferns, L. Forster, A. Stewart-Lee, J. Nourooz-Zadeh, and G. A. A. Ferns, L. Forster, A. Stewart-Lee, J. Nourooz-Zadeh, and E. Anggad, "Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit," Atherosclerosis, vol. 100, no. 2, pp. 171–181, 1993.

[20] D. Zapolska-Downar, A. Zapolski-Downar, M. Markiewski, A. Ciechanowicz, M. Kaczmarczyk, and M. Naruszewicz, "Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells," Atherosclerosis, vol. 155, no. 1, pp. 123–130, 2005.

[21] Y.-M. Deng, B. J. Wu, P. K. Witting, and R. Stocker, "Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1," Circulation, vol. 110, no. 13, pp. 1855–1860, 2004.

[22] B. J. Wu, K. Kathir, P. K. Witting et al., "Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging," The Journal of Experimental Medicine, vol. 203, no. 4, pp. 1117–1127, 2006.

[23] S. Y. Park, J. H. Lee, C. D. Kim, B. Y. Rhim, K. W. Hong, and W. S. Lee, "Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats," Brain Research, vol. 1157, no. 1, pp. 112–120, 2007.

[24] T. Yosikawa, K. Mitani, K. Kotosai, M. Nozako, G. Miyakoda, and Y. Yabuuchi, "Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet," Hormone and Metabolic Research, vol. 40, no. 7, pp. 473–478, 2008.

[25] J. H. Kim, K. W. Hong, S. S. Bae, Y.-I. Shin, B. T. Choi, and H. K. Shin, "Probucol plus cilostazol attenuate hypercholesterolemia-induced exacerbation in ischemic brain injury via anti-inflammatory effects," International Journal of Molecular Medicine, vol. 34, no. 3, pp. 687–694, 2014.

[26] J. M. Timmins, L. Ozcan, T. A. Seimon et al., "Calcium/calmol-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways," The Journal of Clinical Investigation, vol. 119, no. 10, pp. 2925–2941, 2009.

[27] M. Zheng, S.-K. Kim, Y. Joe et al., "Sensing endoplasmic reticulum stress by protein kinase RNA-like endoplasmic reticulum kinase promotes adaptive mitochondrial DNA biogenesis and cell survival via heme oxygenase-1/carbon monoxide activity," The FASEB Journal, vol. 26, no. 6, pp. 2558–2568, 2012.

[28] R. Tenhunen, H. S. Marver, and R. Schmid, "The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase," Proceedings of the National Academy of Sciences of the United States of America, vol. 61, no. 2, pp. 748–755, 1968.

[29] F. W. Booth and D. B. Thomason, "Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models," Physiological Reviews, vol. 71, no. 2, pp. 541–585, 1991.

[30] R. S. Williams, M. Garcia-Moll, J. Mellor, S. Salmons, and W. Harlan, "Adaptation of skeletal muscle to increased contractile activity. Expression nuclear genes encoding mitochondrial proteins," The Journal of Biological Chemistry, vol. 262, no. 6, pp. 2764–2767, 1987.

[31] D. C. Wallace, "Mitochondrial diseases in man and mouse," Science, vol. 283, no. 5407, pp. 1482–1488, 1999.

[32] S. H. Caldwell, R. H. Sverdlow, E. M. Khan et al., "Mitochondrial abnormalities in non-alcoholic steatohepatitis," Journal of Hepatology, vol. 31, no. 3, pp. 430–434, 1999.

[33] A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., "Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities," Gastroenterology, vol. 120, no. 5, pp. 1183–1192, 2001.

[34] K. Begriche, A. Igoudjil, D. Pessayre, and B. Fromenty, "Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it," Mitochondrion, vol. 6, no. 1, pp. 1–28, 2006.

[35] S. Oyadomari, H. P. Harding, Y. Zhang, M. Oyadomari, and D. Ron, "Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice," Cell Metabolism, vol. 7, no. 6, pp. 520–532, 2008.

[36] J.-S. Lee, R. Mendez, H. Heng, Z.-Q. Yang, and K. Zhang, "Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation," American Journal of Translational Research, vol. 4, no. 1, pp. 102–113, 2012.

[37] L. E. Otterbein, F. H. Bach, J. Alam et al., "Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway," Nature Medicine, vol. 6, no. 4, pp. 422–428, 2000.

[38] S. Brouard, L. E. Otterbein, J. Anrather et al., "Carbon monoxide generated by heme oxygenase-1 suppresses endothelial cell apoptosis," The Journal of Experimental Medicine, vol. 192, no. 7, pp. 1015–1026, 2000.

[39] K. D. Poss and S. Tonegawa, "Reduced stress defense in heme oxygenase-1-deficient cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 20, pp. 10925–10930, 1997.

[40] C. A. Piantadosi, C. M. Withers, R. B. Bartz et al., "Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression," The Journal of Biological Chemistry, vol. 286, no. 18, pp. 16374–16385, 2011.

[41] H. B. Suliman, M. S. Carraway, L. G. Tatro, and C. A. Piantadosi, "A new activating role for CO in cardiac mitochondrial biogenesis," Journal of Cell Science, vol. 120, no. 2, pp. 299–308, 2007.

[42] S. Y. Park, S. W. Lee, S. H. Baek et al., "Induction of heme oxygenase-1 expression by cilostazol contributes to its anti-inflammatory effects in J774 murine macrophages," Immunology Letters, vol. 136, no. 2, pp. 138–145, 2011.

[43] F. R. Jornayvaz and G. I. Shulman, "Regulation of mitochondrial biogenesis and its interface with inflammatory processes," Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1820, no. 4, pp. 532–541, 2012.

[44] G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study," Hepatology, vol. 42, no. 1, pp. 44–52, 2005.
[46] S. Kim, Y. Joe, S. O. Jeong et al., “Endoplasmic reticulum stress is sufficient for the induction of IL-1beta production via activation of the NF-kappaB and inflammasome pathways,” *Innate Immunity*, vol. 20, no. 8, pp. 799–815, 2014.

[47] S.-H. Chang, J. Garcia, J. A. Melendez, M. S. Kilberg, and A. Agarwal, “Haem oxygenase 1 gene induction by glucose deprivation is mediated by reactive oxygen species via the mitochondrial electron-transport chain,” *The Biochemical Journal*, vol. 371, no. 3, pp. 877–885, 2003.

[48] J. St-Pierre, S. Drori, M. Uldry et al., “Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators,” *Cell*, vol. 127, no. 2, pp. 397–408, 2006.